Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Fennec Pharmaceuticals Inc. Common Stock

FENC

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Last trade $13.23
Day change +$0.465 (+3.64%)
Day range $11.61 – $13.52
Volume 521,179
Market cap $450M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$450.49M
Price / earnings
222.25×
Price / book
9.16×
Price / sales
6.79×
EV / sales
6.05×
EV / EBITDA
108.07×

Profitability

Earnings per share
$0.06
Return on assets
2.43%
Return on equity
4.12%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.11×
Quick ratio
5.95×
Cash ratio
3.68×

Cash flow

Price / cash flow
142.97×
Price / free cash flow
142.97×
Free cash flow
$3.15M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for FENC, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$19.61M$17.87M$15.11M$13.78M$12.46M$9.65M$8.75M$7.93M
Cost of revenue$838K$721K$570K$1.76M$660K$967K$373K$669K
Gross profit$18.77M$17.15M$14.54M$12.01M$11.8M$8.69M$8.38M$7.26M
Selling, general and administrative$13.96M$15.3M$14.61M$14.55M$11.96M$11.31M$9.09M$8.14M
Research and development$154K$118K$49K$20K$29K$107K$94K$50K
Total operating expenses$14.12M$15.42M$14.66M$14.57M$11.99M$11.42M$9.19M$8.19M
Operating income$4.65M$1.74M-$119K-$2.55M-$189K-$2.73M-$808K-$934K
Interest expense-$1K-$3K-$7K-$308K-$586K-$594K-$592K-$966K
Income before taxes$4.97M$2.02M$201K-$4.68M-$638K-$3.15M-$1.17M-$1.62M
Income taxes$332K$42K$0$106K$0$0$0$365K
Net income$4.64M$1.97M$201K-$4.79M-$638K-$3.15M-$1.17M-$1.99M
Net income attributable to common shareholders$4.64M$1.97M$201K-$4.79M-$638K-$3.15M-$1.17M-$1.99M
EBITDA$4.65M$1.74M-$119K-$2.55M-$189K-$2.73M-$808K-$934K
Basic earnings per share$0.13$0.06$0.01-$0.15-$0.02-$0.11-$0.04-$0.07
Diluted earnings per share$0.12$0.05$0.01-$0.15-$0.02-$0.11-$0.04-$0.08

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

Southpoint Capital Advisors sold 1 million common shares (2.93%) of Fennec Pharmaceuticals on December 24, 2025, at USD $7.50 per share. The firm retains control of 2.7 million shares (approximately 8% of outstanding shares on a fully diluted basis) and may adjust its position based on market conditions.

The Motley Fool

Fennec Q2 Sales Jump 33 Percent

Fennec Pharmaceuticals reported strong Q2 2025 earnings with $9.7 million in net product sales, representing 33% year-over-year growth. The company is expanding internationally through partnerships, securing formulary wins, and preparing for potential milestone events in Europe and Japan.

GlobeNewswire Inc.

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals reported strong first-quarter 2025 financial results, with total net revenues up 18% year-over-year. The company attributed the positive momentum to its refined sales strategy and enhanced patient support services.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.